Daniel R. Whiten

1.9k total citations · 1 hit paper
20 papers, 1.1k citations indexed

About

Daniel R. Whiten is a scholar working on Physiology, Molecular Biology and Neurology. According to data from OpenAlex, Daniel R. Whiten has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 11 papers in Molecular Biology and 6 papers in Neurology. Recurrent topics in Daniel R. Whiten's work include Alzheimer's disease research and treatments (12 papers), Parkinson's Disease Mechanisms and Treatments (4 papers) and Computational Drug Discovery Methods (3 papers). Daniel R. Whiten is often cited by papers focused on Alzheimer's disease research and treatments (12 papers), Parkinson's Disease Mechanisms and Treatments (4 papers) and Computational Drug Discovery Methods (3 papers). Daniel R. Whiten collaborates with scholars based in United Kingdom, Australia and Sweden. Daniel R. Whiten's co-authors include David Klenerman, Christopher M. Dobson, Tuomas P. J. Knowles, Suman De, Michele Vendruscolo, Patrick Flagmeier, Francesco Simone Ruggeri, David C. Wirthensohn, Franziska Kundel and Francesco A. Aprile and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Nature Communications.

In The Last Decade

Daniel R. Whiten

20 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms

2019 387 citations Suman De, David C. Wirthensohn et al. Nature Communications profile →

Peers

Countries citing papers authored by Daniel R. Whiten

Since Specialization

Citations

This map shows the geographic impact of Daniel R. Whiten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel R. Whiten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel R. Whiten more than expected).

Fields of papers citing papers by Daniel R. Whiten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel R. Whiten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel R. Whiten. The network helps show where Daniel R. Whiten may publish in the future.

Co-authorship network of co-authors of Daniel R. Whiten

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel R. Whiten. A scholar is included among the top collaborators of Daniel R. Whiten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel R. Whiten. Daniel R. Whiten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation 2021 ·Science Advances ·(unknown), Sandeep Satapathy, Daniel R. Whiten, Megan A. Kelly, Nicholas J. Geraghty, (unknown), Pietro Sormanni, Michele Vendruscolo, Joel N. Buxbaum, Marie Ranson, Mark R. Wilson	11
2	A Platform for Site‐Specific DNA‐Antibody Bioconjugation by Using Benzoylacrylic‐Labelled Oligonucleotides 2021 ·Angewandte Chemie ·(unknown), (unknown), Daniel R. Whiten, (unknown), Peter Ravn, David Klenerman, Gonçalo J. L. Bernardes	2
3	Single cell morphology distinguishes genotype and drug effect in Hereditary Spastic Paraplegia 2021 ·Scientific Reports ·Gautam Wali, Shlomo Berkovsky, Daniel R. Whiten, Alan Mackay‐Sim, Carolyn M. Sue	15
4	A Platform for Site‐Specific DNA‐Antibody Bioconjugation by Using Benzoylacrylic‐Labelled Oligonucleotides 2021 ·Angewandte Chemie International Edition ·(unknown), (unknown), Daniel R. Whiten, (unknown), Peter Ravn, David Klenerman, Gonçalo J. L. Bernardes	24
5	Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease 2021 ·Brain ·Evgeniia Lobanova, Daniel R. Whiten, Francesco Simone Ruggeri, Christopher G. Taylor, Antonina Kouli, Zengjie Xia, Derya Emin, Yu P. Zhang, Jeff Y. L. Lam, Caroline H. Williams‐Gray, David Klenerman	43
6	PINK1 signalling in neurodegenerative disease 2021 ·Essays in Biochemistry ·Daniel R. Whiten, Dezerae Cox, Carolyn M. Sue	6
7	Alpha Synuclein only Forms Fibrils In Vitro when Larger than its Critical Size of 70 Monomers 2021 ·ChemBioChem ·(unknown), Daniel R. Whiten, Georg Meisl, Francesco Simone Ruggeri, (unknown), David Klenerman	12
8	Tumour necrosis factor induces increased production of extracellular amyloid-β- and α-synuclein-containing aggregates by human Alzheimer’s disease neurons 2020 ·Brain Communications ·Daniel R. Whiten, Philip W. Brownjohn, Steven Moore, Suman De, (unknown), (unknown), Moritz Haneklaus, David Klenerman, Frederick J. Livesey	18
9	Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates 2019 ·Science Advances ·Tom Scheidt, Urszula Łapińska, Janet R. Kumita, Daniel R. Whiten, David Klenerman, Mark R. Wilson, Samuel I. A. Cohen, Sara Linse, Michele Vendruscolo, Christopher M. Dobson, Tuomas P. J. Knowles, Paolo Arosio	126
10	Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms breakdown → 2019 ·Nature Communications ·Suman De, David C. Wirthensohn, Patrick Flagmeier, Craig D. Hughes, Francesco A. Aprile, Francesco Simone Ruggeri, Daniel R. Whiten, Derya Emin, Zengjie Xia, Juan A. Varela, Pietro Sormanni, Franziska Kundel, Tuomas P. J. Knowles, Christopher M. Dobson, Clare Bryant, Michele Vendruscolo, David Klenerman	387
11	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression 2019 ·Acta Neuropathologica Communications ·Suman De, Daniel R. Whiten, Francesco Simone Ruggeri, Craig D. Hughes, Margarida Rodrigues, (unknown), Christopher G. Taylor, Francesco A. Aprile, Serge Muyldermans, Tuomas P. J. Knowles, Michele Vendruscolo, Clare Bryant, Kaj Blennow, Ingmar Skoog, Silke Kern, Henrik Zetterberg, David Klenerman	75
12	The small heat shock protein Hsp27 binds α-synuclein fibrils, preventing elongation and cytotoxicity 2018 ·Journal of Biological Chemistry ·Dezerae Cox, Daniel R. Whiten, James W. Brown, Mathew H. Horrocks, Rebecca San Gil, Christopher M. Dobson, David Klenerman, Antoine M. van Oijen, Heath Ecroyd	103
13	Single-Molecule Characterization of the Interactions between Extracellular Chaperones and Toxic α-Synuclein Oligomers 2018 ·Cell Reports ·Daniel R. Whiten, Dezerae Cox, Mathew H. Horrocks, Christopher G. Taylor, Suman De, Patrick Flagmeier, Laura Tosatto, Janet R. Kumita, Heath Ecroyd, Christopher M. Dobson, David Klenerman, Mark R. Wilson	58
14	Shedding light on aberrant interactions – a review of modern tools for studying protein aggregates 2018 ·FEBS Journal ·Franziska Kundel, Laura Tosatto, Daniel R. Whiten, David C. Wirthensohn, Mathew H. Horrocks, David Klenerman	13
15	Quantifying Co-Oligomer Formation by α-Synuclein 2018 ·ACS Nano ·Marija Iljina, Alexander J. Dear, Gonzalo Garcia, Suman De, Laura Tosatto, Patrick Flagmeier, Daniel R. Whiten, Thomas C. T. Michaels, Daan Frenkel, Christopher M. Dobson, Tuomas P. J. Knowles, David Klenerman	39
16	Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells 2018 ·ChemBioChem ·Daniel R. Whiten, (unknown), Laura Calò, (unknown), Suman De, Patrick Flagmeier, David C. Wirthensohn, Franziska Kundel, Rohan T. Ranasinghe, (unknown), Dilan Athauda, Steven F. Lee, Christopher M. Dobson, Sonia Gandhi, M. G. Spillantini, David Klenerman, Mathew H. Horrocks	44
17	Clusterin protects neurons against intracellular proteotoxicity 2017 ·Acta Neuropathologica Communications ·Jenna M. Gregory, Daniel R. Whiten, (unknown), Teresa P. Barros, Janet R. Kumita, Justin J. Yerbury, Sandeep Satapathy, Karina McDade, Colin Smith, Leila M. Luheshi, Christopher M. Dobson, Mark R. Wilson	51
18	Inhibiting the Ca2+ Influx Induced by Human CSF 2017 ·Cell Reports ·Anna Drews, Suman De, Patrick Flagmeier, David C. Wirthensohn, Wei‐Hsin Chen, Daniel R. Whiten, Margarida Rodrigues, Cécile Vincke, Serge Muyldermans, Ross W. Paterson, Catherine F. Slattery, Nick C. Fox, Jonathan M. Schott, Henrik Zetterberg, Christopher M. Dobson, Sonia Gandhi, David Klenerman	18
19	Flow cytometric measurement of the cellular propagation of TDP-43 aggregation 2017 ·Prion ·Rafaa Zeineddine, Daniel R. Whiten, Natalie E. Farrawell, Luke McAlary, (unknown), Janet R. Kumita, Mark R. Wilson, Justin J. Yerbury	22
20	Rapid flow cytometric measurement of protein inclusions and nuclear trafficking 2016 ·Scientific Reports ·Daniel R. Whiten, Rebecca San Gil, Luke McAlary, Justin J. Yerbury, Heath Ecroyd, Mark R. Wilson	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact